Dataset Information

Prognosis of patients with TX stage differentiated thyroid cancer: propensity scored matching analysis of the SEER database 2004-2013.

ABSTRACT: In differentiated thyroid cancer (DTC), TX stage is defined as 'primary tumour cannot be assessed'. The prognosis of patients with TX stage remains unclear. The aim of this study was to investigate the prognosis of TX stage and provide a perspective on treatment guidelines. We investigated a large cohort of DTC patients from the Surveillance, Epidemiology, and End Results database between 2004 and 2013. Patient mortality was examined by Kaplan-Meier analyses with log-rank tests and Cox proportional hazards regression analyses. The rate of cancer-specific mortality per 1000 person-years for patients with TX stage was higher than for patients with T1-T3 stage, but lower than for patients with T4 stage. The all-cause mortality per 1000 person-years for TX stage patients was also higher than for T1-T3 stage patients, but lower than for T4 stage patients. TX stage showed significant risk for cancer-specific mortality compared to T1 and T4 stages, but not T2 and T3 stages, after adjusting for influential risk factors. TX stage patients showed no significant risk for all-cause mortality compared to T2-T3 stage patients, but were different than T1 and T4 stage patients. These results provide new implications for the treatment of TX stage DTC patients.

SUBMITTER: Xiong Y

PROVIDER: S-EPMC6079136 | biostudies-literature | 2018

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Prognosis of patients with TX stage differentiated thyroid cancer: propensity scored matching analysis of the SEER database 2004-2013.

Xiong Yiquan Y Zhao Qiuyang Q Liu Chunping C Wang Shuntao S Liu Zeming Z Huang Tao T

American journal of translational research 20180715 7

In differentiated thyroid cancer (DTC), TX stage is defined as 'primary tumour cannot be assessed'. The prognosis of patients with TX stage remains unclear. The aim of this study was to investigate the prognosis of TX stage and provide a perspective on treatment guidelines. We investigated a large cohort of DTC patients from the Surveillance, Epidemiology, and End Results database between 2004 and 2013. Patient mortality was examined by Kaplan-Meier analyses with log-rank tests and Cox proportio ...[more]

PMID: 30093938

Similar Datasets

Project description:BackgroundThere is no clear consensus on the benefits of adjuvant chemotherapy for tumor-node-metastasis (TNM) stage T1 (T1N0M0) breast cancer (BC). Our study investigated the effects of adjuvant chemotherapy on T1N0M0 BC patients.MethodsSeventy-five thousand one hundred thirty-nine patients diagnosed with T1N0M0 BC were selected from the Surveillance, Epidemiology, and End Results (SEER) database. Multivariate Cox analyses were performed to investigate the effects of adjuvant chemotherapy on T1a, T1b, and T1cN0M0 BC, including various tumor grades, and four molecular subtypes. Propensity score matching (PSM) was used to eliminate confounding factors and further compare the results between adjuvant chemotherapy and no adjuvant chemotherapy. Additionally, 545 T1N0M0 BC patients treated at the Northern Jiangsu People's Hospital were included as an independent external validation cohort. Univariate and multivariate Cox analyses were used to confirm the effects of adjuvant chemotherapy in T1a, T1b, and T1cN0M0 BC. Survival curves for the different tumor grades and molecular subtypes were plotted using the Kaplan-Meier method.ResultsAdjuvant chemotherapy demonstrated a statistically significant improvement in overall survival (OS) in T1b and T1c BC, but not in T1a BC. Within T1b BC, adjuvant chemotherapy was found to have effects on grade III, and hormone receptor + (HoR +)/human epidermal growth factor receptor 2 + (HER2 +), HoR-/HER2 + , and HoR-/HER2- molecular subtypes, respectively. Adjuvant chemotherapy was beneficial to OS for grade II/III and T1c BC. Identical results were obtained after PSM. We also obtained similar results with external validation cohort, except that adjuvant chemotherapy made a difference in grade II and T1b BC of the external validation dataset.ConclusionsPartial T1N0M0 BC patients with grade III T1bN0M0, patients with tumor grade II and III T1cN0M0, and excluding those with HoR + /HER2- subtype tumors, could obtain OS benefits from adjuvant chemotherapy.

Dataset Information

Prognosis of patients with TX stage differentiated thyroid cancer: propensity scored matching analysis of the SEER database 2004-2013.

Publications

Prognosis of patients with TX stage differentiated thyroid cancer: propensity scored matching analysis of the SEER database 2004-2013.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets